Pacific Shuanglin Bio-pharmacy Co., LTD

000403.SZ

000403.SZPacific Shuanglin Bio-pharmacy Co., LTD

Shenzhen

21.72

CNY

-0.32

(-1.45%)

1.09EPS

19.93P/E

15.83BMarket Cap

Oct 28Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

ISIN

CNE000000F14

Return %

Stock

S&P500

7.05

26.92

-17.29

27.56

79.50

87.11

Use logarithmic scale

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	TTM
Revenue per Share	1.1	0.89	0.91	0.92	0.92	1.05	1.29	1.62	1.87	2.14	2.79	3.29	3.19	3.77
Basic EPS, GAAP	0.1	0.06	0.13	0.23	0.14	0.09	0.04	0.15	0.33	0.38	0.55	0.8	0.84	1.09
Free Cash Flow per Basic Share	0.14	-0.11	-0.14	0.01	0.02	-0.07	-0.1	0.15	0.31	0.32	0.12	0.2	0.41	-0.48
Dividend per Share	0.01	0.02	0.03	0.02	0.01	0.06	0.01	0.04	0.3	0.37	0.02	0.07	0.09	0.3
Book Value per Share	-0.09	-0.01	0.24	0.47	0.57	0.67	0.71	0.87	1.23	1.77	2.1	2.76	3.52	3.73
Tangible Book Value per Share	0.4	0.33	0.47	0.73	0.84	0.86	0.89	1.04	1.49	1.79	4.9	5.44	6.2	6.44
Basic Weighted Avg Shares	418	530	528	532	541	532	532	532	489	490	706	731	730	731
Sales/Revenue/Turnover	461	470	478	489	500	561	685	860	916	1,050	1,972	2,405	2,329	2,756
Operating Margin (%)	35.92	32.92	28.07	29.69	21.28	15.8	17.7	14.49	22.55	21.23	22.8	25.42	27.76	31.79
Depreciation Expense	34	30	30	46	48	49	48	49	46	47	116	126	145	- -
Net Income, GAAP	41	33	70	123	78	50	22	80	160	186	391	587	612	796
Effective Tax Rate (%)	88.05	90.73	27.79	27.67	27.55	36.56	65.68	23.21	16.49	15.89	14.51	11.01	11.14	11.58
Profit Margin (%)	8.83	6.93	14.71	25.03	15.5	8.93	3.15	9.3	17.52	17.71	19.83	24.41	26.29	28.88
Working Capital	-139	-367	-339	-265	-260	-72	-11	87	339	227	1,827	2,088	2,504	2,499
LT Debt	- -	- -	92	72	47	24	23	9	9	42	21	82	218	243
Total Equity	283	288	352	459	525	527	542	622	802	967	6,328	6,861	7,422	7,609
Return on Invested Capital (%)	3.58	2.56	15.22	14.49	9.74	7.02	5.35	11.86	19.57	16.33	9.78	7.89	7.54	9.93
Return on Capital (%)	26.47	21.24	30.27	30.64	18.69	12.93	6.21	16.84	26.72	20.85	27.76	29.71	22.79	27.42
Return on Common Equity (%)	- -	- -	- -	65.52	27.84	15	5.84	18.97	30.13	25.32	33.27	33.52	26.69	32.99

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	19.22%	25.55%	-3.18%
Net Income, GAAP	49.69%	56.24%	4.25%
Free Cash Flow	-42.18%	44.9%	107.27%
Total Cash Common Dividend	130.78%	159.67%	34.48%
Total Equity	68.34%	124.12%	8.17%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Ms. Yehong Wang
Full Time Employees: 2,426
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Address: High-Tech International Building Taiyuan People's Republic of China 030006
IPO Date: Invalid Date
Website: www.slbiop.com
Business: Pacific Shuanglin Bio-pharmacy Co., Ltd. engages in the biochemical engineering, pharmaceutical industry equipment, and medical materials businesses in China. Its lead products include human serum albumin, human immunoglobulin, intravenous human immunoglobulin (PH4), human rabies immunoglobulin, hepatitis B human immunoglobulin, tetanus human immunoglobulin, tianqi analgesic cream, musk herd cream, musk bone paste, anti-inflammatory analgesic cream, dieshangling plasters, and medical gauzes. The company is also involved in the development of porcine pulmonary surfactants, shaqifang compounds, a1-protease inhibitors, human coagulation factor VIII products, and human fibrinogens. In addition, it engages in the investment, consultation, and technology promotion of pharmaceutical and biotechnology development projects; real estate development; and electronic product information consultation, as well as in the provision of electricity. The company was formerly known as Southern Shuanglin Bio-pharmacy Co., Ltd. and changed its name to Pacific Shuanglin Bio-pharmacy Co., Ltd. in April 2021. Pacific Shuanglin Bio-pharmacy Co., Ltd. is based in Taiyuan, China.

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	TTM
Revenue per Share	1.1	0.89	0.91	0.92	0.92	1.05	1.29	1.62	1.87	2.14	2.79	3.29	3.19	3.77
Basic EPS, GAAP	0.1	0.06	0.13	0.23	0.14	0.09	0.04	0.15	0.33	0.38	0.55	0.8	0.84	1.09
Free Cash Flow per Basic Share	0.14	-0.11	-0.14	0.01	0.02	-0.07	-0.1	0.15	0.31	0.32	0.12	0.2	0.41	-0.48
Dividend per Share	0.01	0.02	0.03	0.02	0.01	0.06	0.01	0.04	0.3	0.37	0.02	0.07	0.09	0.3
Book Value per Share	-0.09	-0.01	0.24	0.47	0.57	0.67	0.71	0.87	1.23	1.77	2.1	2.76	3.52	3.73
Tangible Book Value per Share	0.4	0.33	0.47	0.73	0.84	0.86	0.89	1.04	1.49	1.79	4.9	5.44	6.2	6.44
Basic Weighted Avg Shares	418	530	528	532	541	532	532	532	489	490	706	731	730	731
Sales/Revenue/Turnover	461	470	478	489	500	561	685	860	916	1,050	1,972	2,405	2,329	2,756
Operating Margin (%)	35.92	32.92	28.07	29.69	21.28	15.8	17.7	14.49	22.55	21.23	22.8	25.42	27.76	31.79
Depreciation Expense	34	30	30	46	48	49	48	49	46	47	116	126	145	- -
Net Income, GAAP	41	33	70	123	78	50	22	80	160	186	391	587	612	796
Effective Tax Rate (%)	88.05	90.73	27.79	27.67	27.55	36.56	65.68	23.21	16.49	15.89	14.51	11.01	11.14	11.58
Profit Margin (%)	8.83	6.93	14.71	25.03	15.5	8.93	3.15	9.3	17.52	17.71	19.83	24.41	26.29	28.88
Working Capital	-139	-367	-339	-265	-260	-72	-11	87	339	227	1,827	2,088	2,504	2,499
LT Debt	- -	- -	92	72	47	24	23	9	9	42	21	82	218	243
Total Equity	283	288	352	459	525	527	542	622	802	967	6,328	6,861	7,422	7,609
Return on Invested Capital (%)	3.58	2.56	15.22	14.49	9.74	7.02	5.35	11.86	19.57	16.33	9.78	7.89	7.54	9.93
Return on Capital (%)	26.47	21.24	30.27	30.64	18.69	12.93	6.21	16.84	26.72	20.85	27.76	29.71	22.79	27.42
Return on Common Equity (%)	- -	- -	- -	65.52	27.84	15	5.84	18.97	30.13	25.32	33.27	33.52	26.69	32.99

	Dec'23	Mar'24	Jun'24
Total Current Assets	3,426	3,442	3,420
Accounts Receivable, Net	584	486	514
Cash, Cash Equivalents & STI	1,853	1,759	1,704
Inventories	909	1,105	1,140
Total Current Liabilities	922	859	920
Payables & Accruals	- -	- -	- -
ST Debt	278	300	289
Deferred Revenue	- -	- -	- -

	Dec'23	Mar'24	Jun'24
ST Debt	278	300	289
LT Borrowings	196	228	223
LT Finance Leases	21	20	20
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	733	733	733
Market Capitalization	19,772	20,408	19,480

Year	Q1	Q2	Q3	Q4	FY
2022	500	491	502	912	2,405
2023	261	448	666	954	2,329
2024	436	701	- -	- -	- -

Pacific Shuanglin Bio-pharmacy Co., LTD

Growth Rates

(avg. rate of change)

Company Description

Growth Rates

(avg. rate of change)

Working Capital

Capital Structure

Quarterly Revenue

Year

Quarterly Earnings Per Share

Year

Quarterly Dividends Per Share

Year